

November 12, 2021

**The General Manager
Department of Corporate Services - CRD
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001**

Dear Sir,

Subject: Outcome of Board Meeting.

This is with reference to our letter dated 03rd November 2021.

At the meeting of the Board of Directors of the company held on 12th November 2021 the following decisions have been taken:

- 1) Approved the Unaudited Standalone and Consolidated Financial Results along with Limited Review Report of the Company for the quarter and Half Year ended on 30th September 2021.

The meeting commenced at 11.00 a.m. and concluded at 12.15 p.m.

This is for your information and records.

Thanking you

Yours Sincerely

For **TRANSGENE BIOTEK LIMITED**



**DR. K. KOTESWARA RAO
CHAIRMAN & MANAGING DIRECTOR
DIN: 02287235**

TRANSGENE BIOTEK LIMITED

Plot No:69 & 70, IDA Bollaram, Sangareddy District. IDA Bollaram Hyderabad TG 502325 IN

CIN NO: L85195TG1990PLC011065
Standalone Statement of assets and liabilities

Particulars	As at September 30, 2021	As at March 31, 2021
ASSETS		
Non-current assets		
Property, plant and equipment	194,06,670	202,94,953
Capital Work in Progress	-	-
Other intangible assets	1443,97,233	1929,19,335
Intangible assets under development	186,76,633	186,76,633
Financial assets		
(a) Investments	99,990	99,990
(b) Loans	2302,04,250	2302,04,250
Other non-current assets	14,38,583	13,78,696
Total Non - Current Assets	4142,23,359	4635,73,857
Current Assets		
Inventories	2,05,100	2,05,100
Financial assets		
(a) Cash and cash equivalents	95,079	1,41,743
Current Tax Assets	-	-
Other current assets	59,18,298	60,13,088
Total Current assets	62,18,477	63,59,931
Total Assets	4204,41,836	4699,33,788
EQUITY AND LIABILITIES		
Equity		
Equity share capital	7577,00,000	7577,00,000
Other equity	(7632,02,395)	(7110,61,972)
Equity attributable to owners of the Company	(55,02,395)	466,38,028
Total Equity	(55,02,395)	466,38,028
Non-current liabilities		
Financial Liabilities		
(a) Borrowings	465,56,068	454,22,168
Provisions	2302,04,250	2302,04,250
Other non-current liabilities	61,38,583	70,15,523
Total Non-current liabilities	2828,98,901	2826,41,941
Current liabilities		
Financial liabilities		
(a) Borrowings	695,27,576	678,77,576
(b) Trade payables	20,22,989	23,95,852
Provisions	693,54,790	693,49,390
Other current liabilities	21,39,975	10,31,002
Total Current liabilities	1430,45,330	1406,53,820
Total liabilities		
Total Equity and liabilities	4204,41,836	4699,33,788

For TRANSGENE BIOTEK LIMITED


Managing Director

Date: 12.11.2021

Place:Hyderabad

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED SEPTEMBER 30,2021

(Amount in Rs.)

Sr. No.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30.09.2021 (Unaudited)	30.06.2021 (Unaudited)	30.09.2020 (Audited)	30.09.2021 (UnAudited)	30-09-2020 (Audited)	31.03.2021 (Audited)
1	Revenue from operations	16,949	-	-	16,949	-	16,95,499
2	Other income (net)	4,38,470	4,38,470	4,38,470	8,76,940	8,76,940	26,68,984
3	Total income (1 + 2)	4,55,419	4,38,470	4,38,470	8,93,889	8,76,940	43,64,483
4	EXPENSES						
	Cost of materials consumed	31,639	60,919	95,267	92,558	1,37,345	6,08,280
	Changes in inventories of finished goods, work-in-progress and Stock-in-trade	-	-	-	-	-	-
	Employee benefits expense	6,54,777	6,55,821	7,51,572	13,10,598	14,84,445	24,59,236
	Finance costs	5,66,950	5,66,950	6,65,681	11,33,900	13,31,362	26,62,723
	Depreciation and amortisation expense	247,05,193	247,05,193	247,42,519	494,10,385	494,85,038	990,80,463
	Other expenses	5,24,922	5,61,949	9,18,266	10,86,871	15,42,649	38,85,247
	Total expenses	264,83,481	265,50,832	271,73,305	530,34,312	539,80,839	1086,95,949
5	Profit before exceptional items, share of profit from associate & joint venture and tax (3 - 4)	(260,28,062)	(261,12,362)	(267,34,835)	(521,40,423)	(531,03,899)	(1043,31,466)
6	Exceptional item (net)	-	-	-	-	-	-
7	Profit before tax (5 - 6)	(260,28,062)	(261,12,362)	(267,34,835)	(521,40,423)	(531,03,899)	(1043,31,466)
8	Tax expense						
	Tax adjustments for earlier years	-	-	-	-	-	-
	Current tax	-	-	-	-	-	-
	Deferred tax	-	-	-	-	-	-
	Total tax expense	-	-	-	-	-	-
9	Profit for the year (7 - 8)	(260,28,062)	(261,12,362)	(267,34,835)	(521,40,423)	(531,03,899)	(1043,31,466)
10	Other comprehensive income						
	A Items that will not be reclassified subsequently to profit or loss						
	(a) Remeasurements cost of post employment benefits	-	-	-	-	-	-
	Total other comprehensive income	-	-	-	-	-	-
11	Total comprehensive income for the year (9 + 10)	(260,28,062)	(261,12,362)	(267,34,835)	(521,40,423)	(531,03,899)	(1043,31,466)
12	Earnings per equity share						
	(Equity shares, par value of Rs. 10 each)	757,70,000	757,70,000	757,70,000	757,70,000	757,70,000	757,70,000
	Basic (Rs.)	(0.34)	(0.34)	(0.35)	(0.69)	(0.70)	(1.38)
	Diluted (Rs.)	(0.34)	(0.34)	(0.35)	(0.69)	(0.70)	(1.38)

NOTES TO THE ACCOUNTS – Q2 2021-22
1. TrabiORAL & Intra-Nasal delivery:

As presented at the AGM on 30th September 2021, the management has initiated steps for seeking regulatory approvals for undertaking relevant studies leading to get manufacturing and marketing licenses to facilitate launching of “Nozulin” in 2022-23.

2. No. of investor complaints pending at the beginning of the quarter - 0; received complaint during the quarter - 0

3. The auditors have carried out a limited review of the above financial results and these were reviewed by the Audit committee and taken on record by the Board of Directors of the Company at their meeting held on 1st November 2021.

For TRANSGENE BIOTEK LIMITED


Dr.K.Koteswara Rao
Managing Director

Date: 12.11.2021
Place: Hyderabad

TRANSGENE BIOTEK LIMITED

69 & 70, Anrich Industrial Area, Bollaram, Sangareddy DISTRICT.

Standalone Unaudited Statement of Cash Flows for the half year ended September 30, 2021

Particulars	For the Half year ended September,2021 (Un Audited)		For the Half year ended September,2020 (Audited)	
A. CASH FLOW FROM OPERATING ACTIVITIES				
Profit before tax		(521,40,423)		(531,03,899)
<u>Adjustments for :</u>				
Depreciation and amortisation expense	494,10,385		494,85,038	
Finance costs	11,33,900		13,31,362	
Amortisation of government grant	(8,76,940)		(8,76,940)	
Supplier Advances Written off	-		-	
Liabilities / provisions no longer required written back	-		-	
Bad debts written off	-		-	
Non Cash Income	-		-	
Other Non cash Expenses	-		-	
Operating profit before working capital changes		(24,73,078)		(31,64,439)
<u>Changes in working capital:</u>				
<u>Adjustments for (increase) / decrease in operating assets:</u>				
Trade receivables	-			
Other Current assets	94,790		(36,305)	
Inventories	-		-	
<u>Adjustments for increase / (decrease) in operating liabilities:</u>				
Trade payables	(3,72,863)		(4,80,422)	
Provision (CL)	5,400		25,323	
Borrowing (CL)	16,50,001		39,69,852	
Other current liabilities	11,08,973		(2,57,714)	
Cash generated from operations		13,223		56,295
Net income tax paid		-		-
Net cash flow from operating activities (A)		13,223		56,295
B. CASH FLOW FROM INVESTING ACTIVITIES				
Capital expenditure on fixed assets, including capital advances	-		(19,589)	
Sale of Assets	-		-	
Interest Received	-		-	
Loan to other parties	-		-	
Non Current Assets	(59,887)		(1,34,174)	
Net cash (used in) / flow from investing activities (B)		(59,887)		(1,53,763)
C. CASH FLOW FROM FINANCING ACTIVITIES				
Proceeds from issue of equity shares	-			
Finance costs				
Proceeds from Borrowings	-		-	
Payment of Borrowing	-			
Net cash flow (used in) financing activities (C)		-		-
Net (decrease) in Cash and cash equivalents (A+B+C)		(46,664)		(97,468)
Cash and cash equivalents at the beginning of the year		1,41,743		3,89,905
Effect of exchange differences on translation of foreign currency Cash and cash equivalents		-		-
		-		-
Cash and cash equivalents at the end of the year		95,079		2,92,437

For TRANSGENE BIOTEK LIMITED



Dr.K.Koteswara Rao

Managing Director

Date: 12-11-2021

Place:Hyderabad

TRANSGENE BIOTEK LIMITED

Plot No:69 & 70, IDA Bollaram, Sangareddy District. IDA Bollaram Hyderabad TG 502325 IN

CIN NO: L85195TG1990PLC011065
Consolidated Statement of assets and liabilities

Particulars	As at September 30, 2021	As at March 31, 2021
ASSETS		
Non-current assets		
Property, plant and equipment	194,06,670	202,94,953
Capital Work in Progress	-	-
Other intangible assets	1443,97,233	1929,19,335
Intangible assets under development	186,76,633	186,76,633
Financial assets		
(a) Investments	-	-
(b) Loans	13290,24,004	13290,24,004
Other non-current assets	14,38,583	13,78,696
Total Non - Current Assets	15129,43,123	15622,93,621
Current Assets		
Inventories	2,05,100	2,05,100
Financial assets		
(a) Cash and cash equivalents	95,079	2,41,743
(b) Trade Receivables	84,460	84,460
Current Tax Assets	-	-
Other current assets	59,97,716	59,97,716
Total Current assets	63,82,355	65,29,019
Total Assets	15193,25,477	15688,22,640
EQUITY AND LIABILITIES		
Equity		
Equity share capital	7577,00,010	7577,00,010
Other equity	(5874,54,803)	(5353,09,169)
Equity attributable to owners of the Company	1702,45,207	2223,90,841
Total Equity	1702,45,207	2223,90,841
Non-current liabilities		
Financial Liabilities		
(a) Borrowings	465,56,068	454,22,168
Provisions	11522,13,978	11522,13,978
Other non-current liabilities	61,38,583	70,15,523
Total Non-current liabilities	12049,08,629	12046,51,669
Current liabilities		
Financial liabilities		
(a) Borrowings	695,27,576	678,77,576
(b) Trade payables	20,22,989	23,95,852
(c) Other Financial Liabilities	11,26,311	11,26,311
Provisions	693,54,790	693,49,390
Other current liabilities	21,39,975	10,31,002
Total Current liabilities	1441,71,641	1417,80,131
Total liabilities		
Total Equity and liabilities	15193,25,477	15688,22,640

For TRANSGENE BIOTEK LIMITED


Dr.K.Koteswara Rao
 Managing Director

Date: 12-11-2021

Place:Hyderabad



TRANSGENE BIOTEK LIMITED

Plot No:69 & 70, IDA Bollaram, Sangareddy District. IDA Bollaram Hyderabad TG 502325 IN

CIN NO: L85195TG1990PLC011065

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED SEPTEMBER 30,2021

(Amount in Rs.)

Sr. No.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30.09.2021 (Unaudited)	30.06.2021 (Unaudited)	30.09.2020 (Audited)	30.09.2021 (UnAudited)	30-09-2020 (Audited)	31.03.2021 (Audited)
1	Revenue from operations	16,949	-	-	16,949	-	16,95,499
2	Other income (net)	4,38,470	4,38,470	4,38,470	8,76,940	8,76,940	26,68,984
3	Total income (1 + 2)	4,55,419	4,38,470	4,38,470	8,93,889	8,76,940	43,64,483
4	EXPENSES						
	Cost of materials consumed	31,639	60,919	95,267	92,558	1,37,345	6,08,280
	Changes in inventories of finished goods, work-in-progress and Stock-in-trade	-	-	-	-	-	-
	Employee benefits expense	6,54,777	6,55,821	7,51,572	13,10,598	14,84,445	24,59,236
	Finance costs	5,66,950	5,66,950	6,65,681	11,33,900	13,31,362	26,62,723
	Depreciation and amortisation expense	247,05,193	247,05,193	247,42,519	494,10,385	494,85,038	990,80,463
	Other expenses	5,30,133	5,61,949	9,18,266	10,92,082	15,42,649	39,00,618
	Total expenses	264,88,691	265,50,832	271,73,305	530,39,523	539,80,839	1087,11,320
5	Profit before exceptional items, share of profit from associate & joint venture and tax (3 - 4)	(260,33,272)	(261,12,362)	(267,34,835)	(521,45,634)	(531,03,899)	(1043,46,837)
6	Exceptional item (net)	-	-	-	-	-	-
7	Profit before tax (5 - 6)	(260,33,272)	(261,12,362)	(267,34,835)	(521,45,634)	(531,03,899)	(1043,46,837)
8	Tax expense						
	Tax adjustments for earlier years	-	-	-	-	-	-
	Current tax	-	-	-	-	-	-
	Deferred tax	-	-	-	-	-	-
	Total tax expense	-	-	-	-	-	-
9	Profit for the year (7 - 8)	(260,33,272)	(261,12,362)	(267,34,835)	(521,45,634)	(531,03,899)	(1043,46,837)
10	Other comprehensive income						
	A Items that will not be reclassified subsequently to profit or loss						
	(a) Remeasurements cost of post employment benefits	-	-	-	-	-	-
	Total other comprehensive income	-	-	-	-	-	-
11	Total comprehensive income for the year (9 + 10)	(260,33,272)	(261,12,362)	(267,34,835)	(521,45,634)	(531,03,899)	(1043,46,837)
12	Earnings per equity share						
	(Equity shares, par value of Rs. 10 each)						
	Basic (Rs.)	757,70,000	757,70,000	757,70,000	757,70,000	757,70,000	757,70,000
	Diluted (Rs.)	(0.34)	(0.34)	(0.35)	(0.69)	(0.70)	(1.38)
		(0.34)	(0.34)	(0.35)	(0.69)	(0.70)	(1.38)

NOTES TO THE ACCOUNTS – Q2 2021-22

1. TrabiORAL & Intra-Nasal delivery:

As presented at the AGM on 30th September 2021, the management has initiated steps for seeking regulatory approvals for undertaking relevant studies leading to get manufacturing and marketing licenses to facilitate launching of “Nozulin” in 2022-23.

2. No. of investor complaints pending at the beginning of the quarter - 0; received complaint during the quarter -0

3. The auditors have carried out a limited review of the above financial results and these were reviewed by the Audit committee and take on record by the Board of Directors of the Company at their meeting held on 12th November 2021.

For TRANSGENE BIOTEK LIMITED

Dr.K.Koteswara Rao

Managing Director

Date: 12-11-2021

Place:Hyderabad

TRANSGENE BIOTEK LIMITED

69 & 70, Anrich Industrial Area, Bollaram, Sangareddy DISTRICT.

Consolidated Unaudited Statement of Cash Flows for the half year ended September 30, 2021

Particulars	For the Half year ended September,2021 (Un Audited)		For the Half year ended September,2020 (Audited)	
A. CASH FLOW FROM OPERATING ACTIVITIES				
Profit before tax		(521,45,634)		(531,03,899)
<u>Adjustments for :</u>				
Depreciation and amortisation expense	494,10,385		494,85,038	
Finance costs	11,33,900		13,31,362	
Amortisation of government grant	(8,76,940)		(8,76,940)	
Supplier Advances Written off	-		-	
Liabilities / provisions no longer required written back	-		-	
Bad debts written off	-		-	
Non Cash Income	-		-	
Other Non cash Expenses	-		-	
Operating profit before working capital changes		(24,78,289)		(31,64,439)
<u>Changes in working capital:</u>				
<i>Adjustments for (increase) / decrease in operating assets:</i>				
Trade receivables	-			
Other Current assets	-		(36,305)	
Inventories	-		-	
<i>Adjustments for increase / (decrease) in operating liabilities:</i>				
Trade payables	(3,72,863)		(4,80,422)	
Provision (CL)	5,400		25,323	
Borrowing (CL)	16,50,001		39,69,852	
Other current liabilities	11,08,973		(2,57,714)	
Cash generated from operations		(86,778)		56,295
Net income tax paid		-		-
Net cash flow from operating activities (A)		(86,778)		56,295
B. CASH FLOW FROM INVESTING ACTIVITIES				
Capital expenditure on fixed assets, including capital advances	-		(19,589)	
Sale of Assets	-		-	
Interest Received	-		-	
Loan to other parties	-		-	
Non Current Assets	(59,887)		(1,34,174)	
Net cash (used in) / flow from investing activities (B)		(59,887)		(1,53,763)
C. CASH FLOW FROM FINANCING ACTIVITIES				
Proceeds from issue of equity shares	-			
Finance costs				
Proceeds from Borrowings	-		-	
Payment of Borrowing	-			
Net cash flow (used in) financing activities (C)		-		-
Net (decrease) in Cash and cash equivalents (A+B+C)		(1,46,665)		(97,468)
Cash and cash equivalents at the beginning of the year		2,41,743		3,89,905
Effect of exchange differences on translation of foreign currency Cash and cash equivalents		-		-
		-		-
Cash and cash equivalents at the end of the year		95,079		2,92,437

For TRANSGENE BIOTEK LIMITED



Dr.K.Koteswara Rao
Managing Director

Date: 12-11-2021

Place:Hyderabad



Limited Review Report

To,
The Board of directors
M/s. Transgene Biotek Limited
Hyderabad


1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Transgene Biotek Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net loss after tax and total comprehensive loss for the quarter ended 30 September 2021 ("the Statement"), being submitted by the parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").
2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities

Name of the entity Relationship


- | | |
|--------------------------------|------------|
| 1. Transgene Biotek HK Limited | Subsidiary |
| 2. PerOral Bio Private Limited | Subsidiary |

2-4-1096, Sri Sai Digambar Tara, Nimboliadda, Kachiguda, Hyderabad - 500 027.
Cell : 9440573588, 7799001213, E-mail : manishadubey.associates@yahoo.co.in



5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the Internal auditors referred to in paragraph below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial results of subsidiaries included in the Statement, whose interim financial results reflect total revenues of Rs. 0 million, total net Loss after tax of Rs. 0 million and total comprehensive loss of Rs. 0 million, for the quarter ended 30 September 2021, as considered in the consolidated unaudited financial results.

For Manisha Dubey & Associates
Chartered Accountants
FR No. 010114S


Manisha Dubey
Proprietor
M No. 212664
Place: Hyderabad
Date: 12.11.2021



**Unique Document Identification Number (UDIN) for this document is
21212664AAAADE1764**



Limited review report

To,
The Board of directors
M/s. Transgene Biotek Limited
Hyderabad

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Transgene Biotek Limited for the quarter ended 30 September 2021 ("the Statement").
2. This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" - ("IndAS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Manisha Dubey & Associates
Chartered Accountants
FRN: 010114S

Manisha Dubey
Proprietor
M No. 212664
Place: Hyderabad
Date: 12.11.2021

